Inventor · disambiguated record
Roy L. Harris
Also filed as: HARRIS III ROY L · HARRIS III ROY LEONARD · HARRIS ROY L
23 granted patents·7 pending applications·328 citations·filing 2007–2024
96Inventor score
Files withCELGENE CORP12SIGNAL PHARM LLC10PERRIN-NINKOVIC SOPHIE3SIGNAL PHARMACEUTICAL LLC3D SIDOCKY NEIL R1
Top patents by PatentIndex Score
30 records- 0198US7981893B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jul 19, 2011·90 cites·10 claims
- 0296US11634407B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Apr 25, 2023·5 cites·66 claims
- 0396US8492381B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Jul 23, 2013·44 cites·21 claims
- 0496US8110578B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2009·Granted Feb 7, 2012·67 cites·28 claims
- 0595US8372976B2Methods of treatment comprising the administration of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2011·Granted Feb 12, 2013·40 cites·1 claims
- 0693US11739075B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Aug 29, 2023·3 cites·17 claims
- 0793US11560371B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 24, 2023·3 cites·18 claims
- 0893US8507492B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Aug 13, 2013·22 cites·20 claims
- 0991US8569494B2Methods of synthesis and purification of heteroaryl compoundsHARRIS ROY L·Filed 2010·Granted Oct 29, 2013·27 cites·23 claims
- 1088US9771371B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2015·Granted Sep 26, 2017·4 cites·6 claims
- 1184US9079900B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2014·Granted Jul 14, 2015·5 cites·27 claims
- 1284US8907087B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Granted Dec 9, 2014·4 cites·11 claims
- 1383US9428509B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted Aug 30, 2016·6 cites·32 claims
- 1483US9346812B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted May 24, 2016·6 cites·30 claims
- 1582US11358952B2Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Jun 14, 2022·1 cites·21 claims
- 1680US10167290B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2017·Granted Jan 1, 2019·1 cites·5 claims
- 1780US2023119470A1PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAYSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 1880US2024217955A1Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 1978US2025188056A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 2077US11945804B2Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Granted Apr 2, 2024·0 cites·23 claims
- 2176US12103920B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Oct 1, 2024·0 cites·15 claims
- 2274US11292796B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2020·Granted Apr 5, 2022·0 cites·5 claims
- 2372US12227490B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Feb 18, 2025·0 cites·18 claims
- 2472US10683298B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Jun 16, 2020·0 cites·8 claims
- 2570US9193692B2Halogen substituted pyrazines as intermediates of mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2014·Granted Nov 24, 2015·0 cites·14 claims
- 2661US2025100995A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 2759US2024368118A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 2859US2024374591A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 2953US9795607B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2016·Granted Oct 24, 2017·0 cites·33 claims
- 3046US2008242694A1Amino-substituted heterocycles, compositions thereof, and methods of treatment therewithD SIDOCKY NEIL R·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Roy L. Harris files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →